Susceptible population included those with previous colonization or infections due to ESBL producers, serious illness with prolonged hospital stay or invasive medical device, prior therapy with fluoroquinolones or oxyimino-b-lactam agents (such as cefuroxime,cefotaxime, ceftriaxone, ceftazidime, or aztreonam)